[1] Shinji Takahashi, et al. Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3. Eur J Pharmacol. 2017 Sep 5;810:26-35. DOI:
10.1016/j.ejphar.2017.05.045[2] Shinji Takahashi, et al. ASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the Kcnh3 gene, is psychoactive in mice. Behav Brain Res. 2020 Jan 27;378:112315. DOI:
10.1016/j.bbr.2019.112315[3] SHINJI TAKAHASHI. The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder.[J]. PLoS ONE, 2018: e0207750. DOI:
10.1371/journal.pone.0207750